Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a Healthcare company (Biotechnology) with a market capitalization of $10.4B. The Maz Rating grades it against the other companies in its sector.
Kymera Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $121.52, Kymera Therapeutics, Inc. trades at 101.8x sales and 7.6x book value. Over the last twelve months it generated about $102M of revenue and a net loss of $309M. It runs an operating margin of -396.1% and a net margin of -341.9%. It shows return on equity of -22.4%, return on invested capital of -23.9% and a free cash flow yield of -2.8%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 11.13. Over the past 52 weeks the share price ranged from $62.91 to $142.92, with a beta of 2.03.
Kymera Therapeutics, Inc. does not currently pay a dividend.
27 Wall Street analyst ratings cover the stock: 24 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Kymera Therapeutics, Inc. (KYMR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 14.1% / 30% · Interest income / Revenue 1529500000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.32% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 1529500000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.32% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 1529500000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.20% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 46.3% / 33.33% · Receivables / Avg Assets (4Q) 0.29% / 33.33% · Interest income / Revenue 1529500000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 55.0% / 33.33% · (Cash+Recv) / Total Assets 55.0% / 33.33% · Interest income / Revenue 1529500000.0% / 5% | Fail |
No. As of September 2026, Kymera Therapeutics, Inc. (KYMR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Kymera Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 1529500000.0% of each dividend: Kymera Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.